Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider David Boyer sold 3,888 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $156.64, for a total transaction of $609,016.32. Following the sale, the insider directly owned 7,799 shares in the company, valued at approximately $1,221,635.36. This represents a 33.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neurocrine Biosciences Stock Up 0.4%
Shares of NASDAQ:NBIX opened at $156.39 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $121.42 and a 12 month high of $162.39. The company’s 50-day moving average price is $138.81 and its two-hundred day moving average price is $139.02. The firm has a market cap of $15.73 billion, a P/E ratio of 24.10, a P/E/G ratio of 1.17 and a beta of 0.34.
Institutional Trading of Neurocrine Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Norges Bank bought a new position in Neurocrine Biosciences during the fourth quarter worth $162,664,000. UBS Group AG boosted its position in Neurocrine Biosciences by 169.8% during the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock worth $139,494,000 after purchasing an additional 618,956 shares during the period. First Trust Advisors LP boosted its position in Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock worth $126,367,000 after purchasing an additional 472,408 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after purchasing an additional 468,405 shares during the period. 92.59% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
